
More than 36 million people worldwide, including 1.2 million in the U.S., are living with an HIV infection. Today's anti-retroviral cocktails block how HIV replicates, matures and gets into uninfected cells, but they can't eradicate the virus. Mike Kent, a researcher in Sandia National Laboratories' Biological and Engineering Sciences Center, is studying a protein called Nef involved in HIV progression to AIDS with the ultimate goal of blocking it. He and his collaborators have developed a new hybrid method to study this HIV protein that compromises the immune system. The method also could work on many other proteins that damage cellular processes and cause diseases.








